A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment

Cécile Vicier; Giulia Baciarello; Julia Arfi-Rouche; Christophe Massard; Yohann Loriot; Laurence Albiges; Isabelle Cojean-Zelek; Karim Fizazi

doi:10.1016/j.clgc.2019.01.010

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment

Cécile Vicier, Giulia Baciarello, Julia Arfi-Rouche, Christophe Massard, Yohann Loriot, Laurence Albiges, Isabelle Cojean-Zelek, Karim Fizazi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

langue originale	Anglais
Pages (de - à)	e485-e487
journal	Clinical Genitourinary Cancer
Volume	17
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.clgc.2019.01.010
état	Publié - 1 juin 2019

Accès au document

10.1016/j.clgc.2019.01.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6cd4c7026cb6446b89a48095983600db,

title = "A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment",

keywords = "Chemotherapy, High dose chemotherapy, Non-seminomatous germ cell tumor, Orchiectomy, Testicular cancer",

author = "C{\'e}cile Vicier and Giulia Baciarello and Julia Arfi-Rouche and Christophe Massard and Yohann Loriot and Laurence Albiges and Isabelle Cojean-Zelek and Karim Fizazi",

note = "Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , and Sanofi ; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis , Incyte , and Pfizer , outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest. Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis, Incyte, and Pfizer, outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest.",

year = "2019",

month = jun,

day = "1",

doi = "10.1016/j.clgc.2019.01.010",

language = "English",

volume = "17",

pages = "e485--e487",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "3",

}

TY - JOUR

T1 - A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment

AU - Vicier, Cécile

AU - Baciarello, Giulia

AU - Arfi-Rouche, Julia

AU - Massard, Christophe

AU - Loriot, Yohann

AU - Albiges, Laurence

AU - Cojean-Zelek, Isabelle

AU - Fizazi, Karim

N1 - Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , and Sanofi ; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis , Incyte , and Pfizer , outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest. Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis, Incyte, and Pfizer, outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest.

PY - 2019/6/1

Y1 - 2019/6/1

KW - Chemotherapy

KW - High dose chemotherapy

KW - Non-seminomatous germ cell tumor

KW - Orchiectomy

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=85061631968&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2019.01.010

DO - 10.1016/j.clgc.2019.01.010

M3 - Article

C2 - 30792009

AN - SCOPUS:85061631968

SN - 1558-7673

VL - 17

SP - e485-e487

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 3

ER -